AI Article Synopsis

  • Combined antiretroviral therapy (cART) has significantly enhanced the quality of life for people living with HIV (PLWH), but many older adults face HIV-associated neurocognitive disorders (HAND).
  • A new biological model using chimeric HIV (EcoHIV) has been developed in rats to study the neurological effects of HIV, but understanding its distribution in the brain remains a challenge.
  • In this study, EcoHIV was modified and injected into mice to investigate whether microglia are the primary cells containing HIV; results show that microglia are indeed the main reservoirs for HIV in the brain, highlighting the model's potential for exploring neurocognitive disorders.

Article Abstract

Combined antiretroviral therapy (cART) has dramatically improved the quality of life for people living with HIV (PLWH). However, over 4 million PLWH are over the age of fifty and experience accompanying HIV-associated neurocognitive disorders (HAND). To understand how HIV impacts the central nervous system, a reliable and feasible model of HIV is necessary. Previously, a novel biological system using chimeric HIV (EcoHIV) inoculation was developed in a rat model to investigate neurocognitive impairments and synaptic dysfunction. Nevertheless, a significant challenge remains in clarifying EcoHIV's neuroanatomical distribution, particularly its differential expression in various cell types in the brain. In the current study, EcoHIV with mScarlet fluorescence labeling was modified and retro-orbitally injected into Tmem119-EGFP knock-in mice (which express enhanced green fluorescence protein primarily in microglia) to determine if microglia are the major cell type responsible for viral expression and reservoirs of HIV in the brain. The current data show that: (1) in vitro, EcoHIV-mScarlet fluorescence signals were predominantly localized in microglia-like cells among primary rodent brain cells; (2) in vivo, injection of EcoHIV-mScarlet into Tmem119-EGFP mice induced significant HIV expression in the mouse brain. The co-localization of mScarlet and EGFP signals suggests that microglia are the main cell type harboring HIV in the brain. Overall, EcoHIV in rodents offers a valuable biological system to study microglial alterations, viral reservoirs in the brain, and the neurological mechanisms of HIV-associated neurocognitive disorders.

Download full-text PDF

Source
http://dx.doi.org/10.3791/67150DOI Listing

Publication Analysis

Top Keywords

hiv-associated neurocognitive
8
neurocognitive disorders
8
biological system
8
brain current
8
cell type
8
hiv brain
8
hiv
7
brain
6
identification ecohiv-infected
4
ecohiv-infected cells
4

Similar Publications

Article Synopsis
  • Combined antiretroviral therapy (cART) has significantly enhanced the quality of life for people living with HIV (PLWH), but many older adults face HIV-associated neurocognitive disorders (HAND).
  • A new biological model using chimeric HIV (EcoHIV) has been developed in rats to study the neurological effects of HIV, but understanding its distribution in the brain remains a challenge.
  • In this study, EcoHIV was modified and injected into mice to investigate whether microglia are the primary cells containing HIV; results show that microglia are indeed the main reservoirs for HIV in the brain, highlighting the model's potential for exploring neurocognitive disorders.
View Article and Find Full Text PDF
Article Synopsis
  • Patient-specific FDG PET can identify abnormal brain activity in HIV patients before and after starting combination antiretroviral therapy (cART).
  • Studies on these changes were limited to a small number of patients and timeframes.
  • The analysis found that abnormal FDG uptake areas decreased significantly after 6 months of cART, suggesting FDG PET may be useful for early monitoring of treatment effects.
View Article and Find Full Text PDF

Effective neuropsychological assessment of people with HIV (PWH) in low- and middle-income countries (LMICs) is hampered by the unavailability of adequate test norms. We aimed to: (1) develop demographically-corrected (regression-based) South African (SA) normative data for an HIV appropriate neuropsychological test battery for Xhosa home-language speakers; (2) compare the utility of those norms to that of (i) internal standardization norms and (ii) US test publisher norms; and (3) determine the criterion validity of the newly-developed norms. 114 controls and 102 demographically comparable Xhosa home-language people living with HIV completed a well-establised, standard HIV neuropsychological test battery assessing seven cognitive domains.

View Article and Find Full Text PDF

Although antiretroviral therapy (ART) has dramatically improved the outlook of the HIV/AIDS pandemic, people living with HIV (PLWH) on suppressive therapy are still at higher risk for a range of comorbidities including cardiovascular disease (CVD) and HIV-associated neurocognitive disorders (HAND), among others. Chronic inflammation and immune activation are thought to be an underlying cause of these comorbidities. Many of the factors thought to drive chronic inflammation and immune activation in HIV overlap with factors known to induce trained immunity.

View Article and Find Full Text PDF

p62 Binding to Protein Kinase C Regulates HIV-1 gp120 V3 Loop Induced Microglial Inflammation.

Inflammation

December 2024

Department of Pathophysiology, Key Laboratory of the State Administration of Traditional Chinese Medicine, Medical College of Jinan University, Guangzhou, Guangdong Province, China.

The main pathogenic mechanism of HIV-associated neurocognitive disorders (HAND) is neuronal apoptosis induced by inflammatory mediators, in which microglial inflammation plays a crucial role. However, the exact pathogenic mechanism remains unclear. Previous studies have shown that the HIV-1 gp120 V3 loop can trigger inflammation in CHME-5 microglia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!